

Venus Remedies joins United Nations Global Compact for sustainable healthcare

19 May 2025 | News

Reinforcing dedication to ethical governance, human rights, and environmental stewardship



Venus Remedies Limited, a Panchkula-based research-driven global pharmaceutical company, has joined the United Nations Global Compact (UNGC), the world's largest corporate sustainability initiative. With this strategic move, the company aligns its operations and strategies with the UNGC's Ten Principles on human rights, labour, environment, and anti-corruption.

As a UNGC participant, Venus Remedies will publish an annual Communication on Progress (CoP) to share updates on its sustainability performance and adherence to the Compact's principles. This global affiliation marks a critical step in the company's mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery.

Further strengthening its role in public health, Venus Remedies has been a long-standing supplier of WHO-prequalified pharmaceuticals to international health agencies. In recent years, the company has secured key supply contracts with UNICEF for the essential antibiotic ceftriaxone, and with the Pan American Health Organization (PAHO) for critical oncology medications. These partnerships enhance the company's impact in delivering vital medicines to underserved populations across Latin America, Africa, and Asia.

Aligned with its commitment to SDG 3 and its ESG-led innovation roadmap, Venus Remedies has made antimicrobial resistance (AMR) a cornerstone of its R&D agenda.

In the area of AMR, Venus Remedies continues to innovate through its critical care pipeline. The company's novel polymyxin B formulation, VRP-034, has been granted Qualified Infectious Disease Product (QIDP) designation by the US Food and Drug Administration under the GAIN (Generating Antibiotic Incentives Now) Act. This designation provides fast-track regulatory review and five additional years of market exclusivity post-approval, accelerating the delivery of next-generation antibiotics for drug-resistant infections.